2020 PQG Conference: From Variants and Genes to Clinical Actions

Thursday, November 5, 2020

9:00-9:10 Opening Remarks, Stellar Abstract Awards

SESSION I: IDENTIFYING CAUSAL GENES AND PATHWAYS
Moderators:  Bogdan Pasaniuc, Gosia Trynka
* last 5 minutes of all session talks reserved for questions and discussion

9:10-10:00
Danielle Posthuma | KEYNOTE SPEAKER
Vrije Universiteit (VU) University Amsterdam, Amsterdam University Medical Center
From GWAS to Function: Bridging the Gap Between Genetics and Neuroscience

10:00-10:35
Nicole Soranzo  | Wellcome Sanger Institute
The allelic architecture of human disease risk factors

10:35-10:50
Olivia Corradin| Whitehead Institute
Identifying pathogenic cell types of individual disease alleles

10:50-11:20  BREAK

11:20-11:55
Dan Geschwind | UCLA School of Medicine
Annotation of chromatin structure and non-coding variation strongly implicates developing brain in neuropsychiatric disorders

11:55-12:30
Yoav Gilad  | University of Chicago
Where Are the Disease-Associated eQTLs?

12:30-12:45
Huwenbo Shi | Harvard T.H. Chan School of Public Health
Enabling transcriptome-wide association studies at cell-type resolution

12:45-1:00  BREAK

SESSION II: FROM CAUSAL GENES AND PATHWAYS TO DRUG DISCOVERY AND PHARMACOGENETICS
Moderators: Xihong Lin, Kyle Vogan

1:00-1:50
Mark McCarthy | KEYNOTE SPEAKER
Genentech
Now we have 400+ Signals for Type 2 Diabetes Risk, What on Earth are we Going to Do with Them?

1:50-2:25
Cecilia Lindgren | Wellcome Trust Centre for Human Genetics
Machine Learning based histology phenotyping to investigate the epidemiologic and genetic basis of adipocyte morphology and cardiometabolic traits

2:25-3:00
Jeff Barrett | Wellcome Sanger Institute
Comprehensive genomic surveillance  of SARS-CoV-2

3:00-3:30 BREAK

3:30-3:45
Mattia Cordioli | Institute for Molecular Medicine Finland, University of Helsinki, Finland
Genetic and environmental determinants of drug adherence and drug purchasing behaviour

3:45-4:20
Matt Nelson | Deerfield
Bending the drug R&D productivity curve with human genetics

4:20-4:35
Kumar Veerapen | MGH / Broad Institute
Assessing the Genetic Contribution of Drug Response Variability in Selective Serotonin Reuptake Inhibitors from 1,711,695 purchases in the Finnish National Drug Registry

4:35-6:00
Virtual Poster Session

Friday, November 6, 2020

SESSION III: POLYGENIC SCORES FOR DISEASE PREVENTION AND CLINICAL ACTION
Moderators: Eimear Kenny, Pete Kraft

 9:00-9:50
Nilanjan Chatterjee | KEYNOTE SPEAKER
School of Medicine, Johns Hopkins University
Polygenic Risk Score: Development, Validation and Application 

9:50-10:25
Lude Franke  | University of Groningen
Reconciling germline and somatic variation through regulatory network integration

10:25-10:55  BREAK

10:55-11:10
Christopher Cassa | Brigham and Women’s Hospital, Harvard Medical School
Assessing clinical risk using polygenic risk and monogenic variants

 11:10-11:45
Lisa Bastarache  | Vanderbilt University
Polygenic and poly-phenomic approaches to disease prediction

11:45- 12:00
Burcu F. Darst | University of Southern California
Polygenic risk score developed in multiethnic prostate cancer GWAS meta-analysis and further investigated with metabolomics

12:00 – 12:35
Sek Kathiresan |  Verve Therapeutics
From reading the genome for risk to rewriting for cardiovascular health

12:35-12:45 Closing Remarks